DaShenLin Pharmaceutical Group Co Ltd banner
D

DaShenLin Pharmaceutical Group Co Ltd
SSE:603233

Watchlist Manager
DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
Watchlist
Price: 17.53 CNY 0.81%
Market Cap: ¥20B

DaShenLin Pharmaceutical Group Co Ltd
Total Equity

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

DaShenLin Pharmaceutical Group Co Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
D
DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
Total Equity
¥7.2B
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
N/A
LBX Pharmacy Chain JSC
SSE:603883
Total Equity
¥6.8B
CAGR 3-Years
2%
CAGR 5-Years
10%
CAGR 10-Years
12%
Yifeng Pharmacy Chain Co Ltd
SSE:603939
Total Equity
¥11.2B
CAGR 3-Years
11%
CAGR 5-Years
16%
CAGR 10-Years
23%
ShuYu Civilian Pharmacy Corp Ltd
SZSE:301017
Total Equity
¥2B
CAGR 3-Years
3%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Yixintang Pharmaceutical Group Co Ltd
SZSE:002727
Total Equity
¥7.3B
CAGR 3-Years
1%
CAGR 5-Years
6%
CAGR 10-Years
13%
A
Anhui Huaren Health Pharmaceutical Co Ltd
SZSE:301408
Total Equity
¥2B
CAGR 3-Years
37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

DaShenLin Pharmaceutical Group Co Ltd
Glance View

Market Cap
20B CNY
Industry
Retail

DaShenLin Pharmaceutical Group Co., Ltd. is a fascinating entity woven into the intricate fabric of China's rapidly evolving healthcare landscape. Stemming from humble origins, the company has blossomed into a significant player in the pharmaceutical industry. DaShenLin's business model adeptly combines the traditional with the modern, strategically positioning itself across the supply and distribution spectrum. Primarily, it operates through an extensive retail network, boasting a formidable chain of pharmacies thoughtfully dotted across various provinces. These pharmacies are more than mere outlets; they serve as community health sanctuaries offering an array of pharmaceutical products and health consultations. The company's commitment to traditional Chinese medicine sets it apart, further establishing a niche by fusing age-old healing practices with contemporary medicinal needs. The company's revenue streams are as diverse as its product offerings. Predominantly, it derives income from the direct sale of pharmaceuticals, encompassing both Western drugs and traditional Chinese medicines. Additionally, DaShenLin capitalizes on its robust wholesale operations, providing a steady pipeline of medicinal products to regional hospitals and clinics. The company thrives on its comprehensive supply chain, which ensures an uninterrupted flow of goods from production to consumers' hands. With a keen emphasis on quality and efficacy, DaShenLin continuously invests in research and development, fostering innovation within its product lines. This strategic focus not only reinforces consumer trust but also secures its competitive edge within a dynamic market landscape.

Intrinsic Value
27.05 CNY
Undervaluation 35%
Intrinsic Value
Price ¥17.53
D

See Also

What is DaShenLin Pharmaceutical Group Co Ltd's Total Equity?
Total Equity
7.2B CNY

Based on the financial report for Sep 30, 2025, DaShenLin Pharmaceutical Group Co Ltd's Total Equity amounts to 7.2B CNY.

What is DaShenLin Pharmaceutical Group Co Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
8%

Over the last year, the Total Equity growth was 5%. The average annual Total Equity growth rates for DaShenLin Pharmaceutical Group Co Ltd have been 6% over the past three years , 8% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett